-
Mashup Score: 7Concurrent [NMDP]: Optimizing Alternative Donor Platforms: Focus on GvHD Prevention - 10 month(s) ago
This NMDP session will focus on optimizing GvHD prevention following alternative donor hematopoietic cell transplantation. Dr. Mahasweta Gooptu will review HLA and non-HLA factors used for alternative donor selection. Dr. Sameem Abedin will provide perspectives on historical and current use of post-transplant cyclophosphamide. Lastly, Dr. Everett Meyer will discuss GvHD prevention using novel pharmaceutical agents and graft manipulation techniques.
Source: tandem.confex.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Siolas Lab | Weill Cornell Medicine - 2 year(s) ago
The Siolas Lab is dedicated to investigating the biology underlying gastrointestinal cancers and advancing novel therapeutics for cancer patients. Dr. Despina Siolas is a physician scientist with a clinical specialty in Gastrointestinal Medical Oncology and a dual research focus in pancreatic cancer and colon cancer. In addition to her clinical work, Dr. Siolas conducts research on cancer genes…
Source: siolaslab.weill.cornell.eduCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @DrDespina123: Did you know we have open positions for #postdoctoral researchers? 👇 https://t.co/M0LkTqGC56 https://t.co/Ll8QTwfWai
-
-
Mashup Score: 0Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients - PubMed - 2 year(s) ago
Based on a prospective cohort study of 1056 patients with sickle cell anemia (Hb SS) initiated in 1959, we investigated the influence of calendar era, age, sex, and prior medical conditions on the subsequent development of irreversible organ damage and survival using the Cox regression model with ti …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
2/ Pts with SCD are at risk of irreversible organ damage. In one of the longest observational studies that followed 1056 SCD patients over 4 decades, 12% of patients developed kidney failure by a median age of 37 yrs https://t.co/CVRnPJjEId
-
-
Mashup Score: 0Haploidentical Allogeneic Stem Cell Transplantation in Sickle Cell Disease: A Systematic Review and Meta-Analysis - PubMed - 2 year(s) ago
Allogeneic hematopoietic stem cell transplantation (SCT) is the sole established curative treatment option for patients with sickle cell disease (SCD). However, a lack of HLA-identical sibling donors is a limiting factor. Haploidentical related donors are a promising donor pool, potentially extendin …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
4/ Until recently, offering a curative HCT to patients with SCD was limited to patients who had a matched donor. Fortunately, the haploidentical transplantation platform, using PTCy, has been greatly optimized in the past decade. https://t.co/Z6TgLSf87M
-
-
Mashup Score: 0
Increasing total body irradiation to 400 cGy substantially reduced graft failure while maintaining the safety of haploidentical bone marrow transplantation with post-transplantation cyclophosphamide. These results suggest that engraftment after haploidentical bone marrow transplantation for haemoglobinopathies is possible, and primary graft failure—the main problem previously reported—might be…
Source: The Lancet HaematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
6/ Now we have very exciting data from augmented conditioning regimens: 1. Hopkins regimen with augmented TBI @GvHD_Meade https://t.co/DxkpxCjaXd
-
-
Mashup Score: 0
Curative therapy for individuals with severe sickle cell disease (SCD) who lack an HLA-identical sibling donor has been frustratingly elusive. In with the goal of improving engraftment while minimizing transplantation-related morbidity, a multi-institutional learning collaborative was developed in t …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
7/ or 2. with additional thiotepa... among others https://t.co/Ref8swMgd1
-
-
Mashup Score: 0
Bone Marrow Transplantation – Haploidentical allogeneic stem cell transplantation with post-transplant cyclophosphamide and subsequent kidney transplant for patients with severe sickle cell disease…
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet-
9/ Here we report a pt with SCD and ESKD undergoing a haplo-HCT Flu/Cy/TBI 400 cGy and review the considerations for future patients. This is not a 'standard of care', but is meant to share our experience and advocate for increased research for these pts. https://t.co/F3qxjK5Z4U
-
1/10 Happy that share our report of a successful haploidentical-HCT with PT-CY in a pt with sickle cell disease + end-stage kidney disease (ESKD) on hemodialysis. Pt is now s/p kidney transplant! https://t.co/F3qxjK5Z4U @WeillCornellBMT https://t.co/vFDqXZ5Lsh #MedTweetorials
-
-
Mashup Score: 8Agenda 2023 en Español | - 2 year(s) ago
Nos complace ofrecer 8 talleres en español, los cuales se enumeran a continuación. Por favor complete su inscripción para obtener acceso a todos los eventos en vivo y grabados durante el simposio. El formulario de inscripción está en inglés, pero si necesita ayuda para completarlo, envíe un correo electrónico a help@bmtinfonet.org y nosotros le ayudaremos a inscribirse. ¡Esperamos ansiosos…
Source: symposium.bmtinfonet.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Looking forward to speaking at the @BMTInfoNet 2023 Celebrating a Second Chance at Life Survivorship Symposium - for #bmtsm #CARTcells patients. There will be a whole track in Spanish‼️. Please share with your Spanish-speaking pts around the🌎. https://t.co/F7WywhonER. https://t.co/HkBPD0FVad
-
-
Mashup Score: 0Agenda 2023 | - 2 year(s) ago
Welcoming Remarks and Keynote Address Welcome: Susan Stewart, Executive Director and Founder, BMT InfoNet You Don’t Know How Strong You Are Until Being Strong is the Only Choice You Have Presenter: Justin Regan RN, Transplant Survivor Out of the Frying Pan and …? Life after Transplant Using…
Source: symposium.bmtinfonet.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
For all patients, please check out the full agenda; there are many important talks on survivorship. @BMTInfoNet https://t.co/PZoXLJPJ09
-
-
Mashup Score: 76
In this observational study, targeted deep DNA sequencing was performed to test the hypothesis that detection of specific residual AML-associated variants in the blood of patients in first remission prior to allogeneic hematopoietic cell transplant would be associated with higher rates of relapse…
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @DrChrisHourigan: DNA Sequencing to Detect Residual Disease for Acute Myeloid Leukemia https://t.co/8KevMvCkCE via @JAMA_current part of…
-
Concurrent [NMDP]: Optimizing Alternative Donor Platforms: Focus on GvHD Prevention #Tandem24 https://t.co/lTOcFNBXvS. Exciting talk from Everett H. Meyer on GvHD Prevention using Graft Manipulation @StanfordBMT_CT https://t.co/M882rTJaFv